RxDoctor Payments Data

Michael Tsovko

Psychiatric/Mental Health · Fort Worth, TXNPI 1447933502

Payments from drug & device makers

$5,110in general payments, 2019–2025

Across 299 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$750
  • Teva Pharmaceuticals USA, Inc.$743
  • AbbVie$645
  • Otsuka America Pharmaceutical, Inc.$491
  • Neurocrine Biosciences, Inc.$392
  • Lundbeck LLC$370
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$4,99998%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,110 in reported general payments places this provider in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$21,559
Medicare patients
76
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole23$981
Bupropion XlBupropion Hcl68$853
Desvenlafaxine Succinate ErDesvenlafaxine Succinate30$851
Quetiapine Fumarate65$829
Mirtazapine56$770
Gabapentin45$525
Eszopiclone21$452
Hydroxyzine Hcl36$424
Prazosin Hcl39$418
Buspirone Hcl38$411
Lamotrigine31$367
Escitalopram Oxalate54$338
Trazodone Hcl79$259
Venlafaxine Hcl ErVenlafaxine Hcl28$257
Lithium Carbonate ErLithium Carbonate32$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$16$14449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →